| Authors: |
Leleu X; Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, 86000, France., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Zonder JA; Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI 48201, USA., Macro M; CHU de Caen, Caen, 14000, France., Ramasamy K; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, OX3 7LE, UK., Hulin C; CHU de Bordeaux, Bordeaux, 33000, France., Silar J; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Kuhn M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA., Bent-Ennakhil N; Takeda Pharmaceuticals International AG, Opfikon, 8152, Switzerland., Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Terpos E; Department of Clinical Therapeutics, National & Kapodistrian University of Athens, School of Medicine, Athens,115 27, Greece. |
